Compare Boston Beer Company Inc (SAM) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Stryker Corporation — how do they compare? Boston Beer Company Inc trades at $172.08 (market cap $1.74B), while Stryker Corporation trades at $278.02 (market cap $116.27B). The key difference: Stryker Corporation is far larger — about 66.8× Boston Beer Company Inc's market cap, and Stryker Corporation pays a 1.16% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| SAM | SYK | |
|---|---|---|
Market Cap | $1.74B | $116.27B |
Sector | Consumer Staples | Technology |
52-Week High | $260.05 | $392.76 |
52-Week Low | $161.08 | $276.43 |
Enterprise Value | $1.50B | $127.74B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAM trades at $162.06, down 3.98% amid bearish technical signals and mixed earnings performance. The stock shows negative profitability margins but positive cash flow trends, with a consensus price target of $207.33. Recent news highlights brand initiatives and a CFO transition, while analyst sentiment remains cautious due to volume declines and cost pressures.
Outlook is guarded with potential upside from valuation discounts and debt-free balance sheet, but risks include sustained volume weakness and competitive pressures. Investors should weigh margin improvements against earnings misses and bearish technical indicators for near-term direction.
Stryker (SYK) trades at $276.43, down 8.81% over 24 hours, reflecting bearish technical signals but strong fundamentals with a P/E of 31.41 and net income margin of 14.43%. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1 2026, while strategic moves like the ZuriMED acquisition and FDA-cleared Apple Vision Pro app highlight innovation. Cash flow improved in 2026, with net cash flow rising to $1.0B from $359M in 2025.
The outlook is positive due to analyst consensus favoring buy ratings (72.55%) and a $376 price target, though risks include competitive pressures and market volatility. Upside potential hinges on execution of growth initiatives, while downside may stem from economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
